The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series C - II | Alive

Total Raised


Last Raised

$40M | 1 yr ago

About AnchorDx

AnchorDx is a precision medicine company engaged in the clinical research & development of targeted DNA methylation high-throughput sequencing solutions for the early diagnosis of cancer.

AnchorDx Headquarter Location

Guangzhou, Guangdong,


+86 020-3443 8809

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing AnchorDx

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned AnchorDx in 1 CB Insights research brief, most recently on Oct 10, 2019.

Expert Collections containing AnchorDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AnchorDx is included in 8 Expert Collections, including Cancer.



3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'


Digital Health

13,551 items


Medical Devices

8,649 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Biopharma Tech

260 items

AnchorDx Patents

AnchorDx has filed 3 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Epigenetics
  • Genetics
patents chart

Application Date

Grant Date


Related Topics



Oncology, Molecular biology, Infectious causes of cancer, Epigenetics, Foramina of the skull


Application Date


Grant Date


Related Topics

Oncology, Molecular biology, Infectious causes of cancer, Epigenetics, Foramina of the skull



Latest AnchorDx News

09:00 EDT AnchorDx's Non-invasive Lung Cancer Early Diagnosis Product, PulmoSeek, Completes EU CE Marking Requirements

Jun 15, 2022

News provided by Share this article Share this article The company obtained a European Access Permit for in-vitro diagnostics devices (IVDD) authorized by the Netherlands CIBG of Ministry of Health, Welfare and Sport. GUANGZHOU, China, June 15, 2022 /PRNewswire/ -- PulmoSeekTM Lung Cancer Early Detection Assay, the non-invasive blood-based cfDNA methylation detection product developed by AnchorDx for the early diagnosis of lung cancer, recently completed the procedure for EU IVDD CE Marking, and obtained IVD reagents licensing signed and issued by the CIBG of Ministry of Health, Welfare and Sport in the Netherlands. The license number is NL-CA002-2022-71591. PulmoSeekTM is applicable for the benign and malignant diagnosis of people with 5-30mm pulmonary nodules. In the earlier stage of prospective clinical studies at 14 centers, the product's excellent performance was well verified in the following: 6-20mm size nodules subgroup, with a sensitivity of 100.0%; Stage I lung cancer subgroup, with a sensitivity of 97.1%; Solid nodules, part-solid nodules, and ground-glass nodules, with a sensitivity of 100.0%, 94.7% and 96.4%, respectively; In head-to-head comparison, PulmoSeekTM outperformed PET-CT, Mayo Model and Veterans Affairs Model, and will provide an innovative non-invasive detection solution for the precise management of patients with pulmonary nodules. Relevant results have been published in renowned international medical journal, The Journal of Clinical Investigation (impact factor: 14.808) in 2021. According to GLOBOCAN 2020 data released by the International Agency for Research on Cancer (IARC), lung cancer is the leading cause of cancer deaths (18%) with more than 2.2 million new cases and 1.8 million deaths annually worldwide. As a screening technology for lung cancer, LDCT has been widely recognized by domestic and international clinical guidelines, but the precise management of patients with pulmonary nodules after LDCT screening has also become an urgent clinical problem to be solved. PulmoSeekTM Lung Cancer Early Detection Assay can achieve early diagnosis and treatment of lung cancer through accurate diagnosis of patients with benign and malignant pulmonary nodules. Currently, several of AnchorDx's products have obtained relevant IVD-related qualifications from US FDA and European Medicines Agency (EMA). PulmoSeek's access permit for the EU market will further promote this innovative precision medical product to benefit more patients with pulmonary nodules around the world forthwith. About AnchorDx AnchorDx is a world-leading developer of cancer screening and early detection solutions based on methylation NGS technology. AnchorDx strives to revolutionize single/multi/pan-cancer early screening, detection technologies, and products. The current product pipeline encompasses more than 70% of all cancers.

AnchorDx Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AnchorDx Rank

  • Where is AnchorDx's headquarters?

    AnchorDx's headquarters is located at Guangzhou.

  • What is AnchorDx's latest funding round?

    AnchorDx's latest funding round is Series C - II.

  • How much did AnchorDx raise?

    AnchorDx raised a total of $73M.

  • Who are the investors of AnchorDx?

    Investors of AnchorDx include Yaoming Huiying Investment, OrbiMed Advisors, Marathon Venture Partners, Sijia Jianxin Fund, ARCH Venture Partners and 6 more.

  • Who are AnchorDx's competitors?

    Competitors of AnchorDx include Tempus.

You May Also Like


Diagu is an internationally operating company that is part of the Microsoft for Start-ups program, working on a solution that will help diagnose patients better, more accurately and faster through an in-depth analysis of their laboratory test results using artificial intelligence.

Mango Sciences

Mango Sciences is an emerging market data science company that connects underrepresented patients to precision medicine. The company's platform utilizes AI analytics to transform deep clinical data into key insights. It is based in Boston, Massachusetts.

nference Logo

nference offers a platform that enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. nference makes biomedical knowledge computable and builds its AI platform to serve as the connective fabric for various silos of information that exist across health care enterprises.

LifeOmic Logo

LifeOmic is the developer of a secure cloud service for the long-term storage, retrieval, analysis, and clinical use of information central to patient care. Its PHC platform integrates and indexes disparate sources including genomic, clinical, imaging, and population data. All of this data is added to a searchable and flexible repository for each patient to deliver precision treatments and accelerate research. LifeOmic's LIFE mobile apps use the Precision Health Clous to empower individuals to be more involved in and take action on their personal health and wellness goals.

Zephyr AI

Zephyr AI is a healthcare technology company committed to reshaping traditional approaches to drug discovery and precision medicine. Through partnerships and proprietary data, Zephyr AI is curating a comprehensive healthcare dataset and marrying it with artificial intelligence algorithms to generate translatable insights to build tools and products that support both patients and providers and fuel ongoing research. The company was founded in 2021 and is based in Dallas, Texas.

NuProbe Logo

NuProbe develops in molecular engineering to realize non-invasive early detection of rare genetic variants in patients. NuProbe takes a multi-platform approach to apply these technology capabilities in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings. The company was founded in 2016 and is based in Houston, Texas.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.